A new study from Karolinska University Hospital and Karolinska Institutet in collaboration with Uppsala University Hospital and Uppsala University shows suspected small vessel disease in young ...

A specific molecule excreted by methane-oxidizing bacteria could be most suitable for therapy against Wilson's disease (WD). This is what researchers led by Helmholtz Munich scientist Hans Zischka ...

Zinc blocks the intestinal absorption of copper from the diet and the reabsorption of endogenously secreted copper. Galzin ® (zinc acetate capsules) is now available for maintenance treatment of ...

Please provide your email address to receive an email when new articles are posted on . Orphalan announced FDA approval of Cuvrior for the treatment of adults with stable Wilson’s disease who are ...

Brand Institute announced it is working with rare disease specialist, Orphalan, in developing the brand name CUVRIOR™, approved by the United States Food and Drug Administration on April 28, 2022.

The approval was based on data from a phase 3 study that compared Cuvrior with penicillamine in 53 adults with Wilson disease. The Food and Drug Administration (FDA) has approved Cuvrior ™ (trientine ...

Monopar Therapeutics has evolved from early radiopharma assets into a more concrete bet with ALXN1840 for rare diseases. Click for this MNPR stock update.

Richard Rosencrantz, M.D.; Michael Schilsky, M.D. On physical exam, patients early on may have hepatomegaly, and over time may be seen to develop signs of chronic liver injury and cirrhosis with ...

A potential new treatment for the rare condition Wilson disease moved a step closer to reality after Alexion Pharmaceuticals Inc., now part of Astrazeneca plc, announced positive top-line results from ...

JAUNDICE is a common presentation of Wilson's disease and may precede the neurologic features by many years. 1, 2 Infective hepatitis is often invoked as an explanation of the initial episode, and ...